Table 2.
At baseline | After placebo | After verum | ||||
---|---|---|---|---|---|---|
p-value [adj. p-value] vs. baseline (n) | p-value [adj. p-value] vs. baseline (n) | p-value [adj. p-value] vs. placebo (n) | ||||
Empagliflozin | ||||||
Homoarginine | 2.66 ± 3.03 | 2.45 ± 2.46 | 0.562 [0.705] (68) | 2.11 ± 2.03 | 0.265 [0.441] (70) | 0.085 [0.213] (69) |
Arginine | 28.39 ± 16.82 | 26.82 ± 18.37 | 0.422 [0.613] (68) | 26.87 ± 15.59 | 0.781 [0.863] (69) | 0.654 [0.795] (70) |
ADMA | 52.01 ± 15.30 | 51.64 ± 14.59 | 0.280 [0.450] (70) | 44.11 ± 14.89 | < 0.001 [< 0.001] (71) | < 0.001 [0.001] (70) |
SDMA | 42.63 ± 12.32 | 40.80 ± 11.00 | 0.102 [0.242] (70) | 41.07 ± 12.65 | 0.114 [0.257] (71) | 0.759 [0.863] (70) |
Creatinine | 10.95 ± 3.93 | 10.57 ± 3.13 | 0.207 [0.373] (70) | 9.62 ± 3.09 | < 0.001 [0.001] (71) | 0.016 [0.048] (70) |
Dapagliflozin | ||||||
Homoarginine | 2.64 ± 5.21 | 2.58 ± 3.66 | 0.734 [0.831] (59) | 2.07 ± 1.58 | 0.443 [0.604] (57) | 0.984 [0.984] (57) |
Arginine | 25.67 ± 17.27 | 30.55 ± 20.44 | 0.007 [0.053] (59) | 32.32 ± 23.70 | 0.006 [0.053] (58) | 0.441 [0.604] (58) |
ADMA | 47.77 ± 15.51 | 50.94 ± 16.97 | 0.174 [0.313] (59) | 47.76 ± 17.90 | 0.923 [0.966] (58) | 0.160 [0.313] (58) |
SDMA | 42.12 ± 12.13 | 44.85 ± 15.03 | 0.521 [0.670] (59) | 41.87 ± 13.07 | 0.801 [0.879] (58) | 0.172 [0.313] (58) |
Creatinine | 10.63 ± 3.96 | 11.15 ± 5.32 | 0.419 [0.604] (59) | 10.22 ± 3.70 | 0.167 [0.313] (58) | 0.069 [0.163] (58) |
Data are given in µmol for hArg, Arg, ADMA, and SDMA, for creatinine in mmol, all as mean ± SD; p-values calculated by Wilcoxon signed-rank test, adj. p-values computed based on the procedure of Benjamini and Hochberg¸ p-values refer to the absolute changes in biomarker amount